Artelo Biosciences Inc Crosses Above 20-Day SMA on Market Sentiment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 02 Dec 25
Source: D
Artelo Biosciences Inc is up 5.46% in pre-market trading, crossing above its 20-day simple moving average (SMA).
This movement comes amid a broader positive sentiment in the market, with the Nasdaq-100 up 0.39% and the S&P 500 up 0.26%.
The upward trend may indicate increased investor confidence in the stock, potentially leading to further gains in the near term.
Analyst Views on ARTL
About ARTL
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
